6. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Pain-relieving NSAIDs block the very enzyme that also protects the gut lining — so they often strain the small intestine and its barrier without any warning signs.
NSAIDs – Silent Disruptors of the Gut Barrier
Non-steroidal anti-inflammatory drugs are common, effective medicines for pain and inflammation [144].
People have been using willow bark to relieve fever and pain for at least 3,500 years. The Edwin Smith Papyrus, an Egyptian surgical text from around 1600 BC, records its use. Hippocrates recommended a brew of willow leaves for pain in childbirth. Medieval herbalists prescribed it for joint swelling. For most of this history, nobody knew why it worked. In 1828, Johann Andreas Buchner, a German pharmacist, isolated the active compound and named it salicin. By the 1870s, salicylic acid had become a widely used medicine – effective, but harsh on the stomach. In 1897, Felix Hoffmann, a chemist at Bayer in Elberfeld, synthesised a more tolerable form: acetylsalicylic acid, marketed from 1899 as Aspirin. It would become, by most measures, the most widely consumed drug in human history. The reason aspirin relieves pain is that it inhibits cyclo-oxygenase enzymes, which produce inflammatory prostaglandins. The reason it also injures the gut is exactly the same: those same enzymes produce the protective prostaglandins that maintain the intestinal mucosal barrier. One molecule. One mechanism. Two opposite consequences in the same organ. That tension is not unique to aspirin – it runs through the entire NSAID drug class, and it shapes every clinical decision about their use.
NSAIDs' effects on the gut microbiota entered the research agenda through an unexpected clinical connection: the observation that NSAID-associated small intestinal injury – a complication distinct from the better-known gastric ulceration – was modifiable by microbiota manipulation. A study by Syer and colleagues at the University of Nottingham, published in Arthritis Research and Therapy in 2015, showed that germ-free[G] rodents did not develop the small intestinal damage seen in conventional animals given NSAIDs, providing direct evidence that the microbiota is required for NSAID enteropathy to occur. [227] The mechanism involves bile acid recycling and bacterial metabolism. NSAIDs enter the enterohepatic circulation, are conjugated in the liver, excreted into bile, and delivered to the small intestine where gut bacteria deconjugate them – regenerating the active compound that then injures the intestinal mucosa. Disrupting the microbiota with antibiotics before NSAID administration reduces enteropathic injury in animal models. [228] The human microbiota effects of chronic NSAID use include reductions in protective SCFA-producing taxa and modest shifts toward gram-negative organisms in some studies. The effect size is smaller than for antibiotics, but the clinical relevance is amplified by the scale of NSAID use: they are among the most widely used medications globally, and chronic use for pain management or cardiovascular prophylaxis exposes large populations to sustained low-level microbiota perturbation. [39] The protective strategy involves the same principle as other medication-associated microbiota disruptions: dietary fiber intake helps maintain SCFA-producing populations, and co-administration of agents that support mucosal integrity – including specific probiotics studied in NSAID enteropathy contexts – may reduce both the gastrointestinal complication rate and the associated microbiota dysregulation.
Ibuprofen, aspirin, and naproxen help many people function day to day, which is why they are used so widely. The trade-off is that the gastrointestinal tract—especially the small intestine—can be sensitive to their effects, sometimes without obvious early warning signs [228].
NSAIDs reduce prostaglandin production by inhibiting cyclooxygenase enzymes. Prostaglandins support mucus secretion, mucosal blood flow, and epithelial repair. When this protection is reduced, the intestinal lining can become more vulnerable, and studies in humans show that intestinal permeability can increase after NSAID exposure. In practical terms, this may allow greater immune exposure to bacterial products and dietary components, particularly in susceptible individuals.
The injury is not limited to the stomach. Modern evaluation methods, including capsule endoscopy, have shown erosions and ulcer-like lesions in the small intestine among NSAID users, and these changes are often clinically quiet. A person may feel little more than mild discomfort—or nothing at all—while microscopic damage and local inflammation develop.
Mechanistically, NSAID-related injury is not explained by prostaglandins alone. Topical, COX-independent effects also contribute, including changes in epithelial energy balance and interactions within the intestinal chemical environment. These processes can amplify mucosal stress and make recovery slower when exposure is frequent or prolonged.
The microbiota may shift during NSAID use through both direct and indirect pathways. Alterations in mucus, barrier function, and local immune signaling can change the habitat in which microbes compete and ferment nutrients. In studies of medication effects on the microbiota, concurrent drugs—particularly acid-suppressing agents—can further modify these patterns, which helps explain why results vary between individuals.
Clinically, long-term or high-dose NSAID use is associated with complications such as occult bleeding and small-bowel injury, and in patients with inflammatory bowel disease there is ongoing debate about whether certain NSAIDs increase the likelihood of flares. The safest summary is that risk appears context-dependent, influenced by drug type, dose, duration, and the patient’s underlying intestinal vulnerability.
NSAIDs remain valuable medicines. A balanced approach recognizes their benefit while acknowledging that gut effects are real and sometimes silent. Thoughtful use—matching dose and duration to clinical need—helps reduce avoidable intestinal stress, especially in patients with prior gastrointestinal disease or persistent digestive symptoms.
NSAIDs – A Balanced Approach to Gut Protection
In clinical decision-making, NSAIDs are best viewed as situational medicines rather than everyday solutions. When pain control is needed, physicians weigh the expected benefit against gastrointestinal vulnerability and consider whether non-NSAID strategies could achieve the same goal.
If longer courses are unavoidable, clinicians may prefer agents with a more selective mechanism and the lowest effective dose, recognizing that individual tolerance varies and that no option is entirely risk-free for the intestine.
The way NSAIDs are taken also matters. Co-administration with food and avoidance of unnecessary combinations—such as overlapping anti-inflammatory products—can moderate local irritation and reduce cumulative exposure.
Attention to the intestinal barrier becomes part of overall care. Rather than relying on single supplements, the emphasis is on supportive dietary patterns and adequate nutrition, which provide the substrates required for mucosal repair and microbial stability.
After periods of NSAID use, clinicians often focus on gradual ecological recovery. Diets containing a variety of plant fibers and minimally processed foods help create conditions in which short-chain-fatty-acid production and microbial diversity can re-establish without aggressive interventions.
Microbiota Effects
- NSAID exposure has been associated with shifts in SCFA-producing bacteria, which may influence epithelial repair and barrier resilience, although changes vary between individuals and drug types [39].
- NSAIDs can increase intestinal permeability, and in susceptible patients this may promote greater immune exposure to bacterial products; progression to clinically relevant systemic inflammation is context-dependent rather than universal [144].
- Alterations in microbial profiles have been reported during NSAID therapy, including relative expansion of Pseudomonadota (formerly Proteobacteria), but these patterns are heterogeneous and strongly influenced by co-medications such as proton-pump inhibitors.
- Mucosal immune responses can be modified by repeated NSAID use, potentially lowering resistance to local infections or bacterial overgrowth in vulnerable individuals.
- The relationship between NSAIDs and inflammatory bowel disease is complex; some studies suggest higher risk of flares with non-selective agents, yet causality remains uncertain and depends on patient-specific factors and exposure characteristics.
Patient Guidance
- Use NSAIDs only when there is a clear need. Avoid taking them for minor or routine discomfort if other options can help.
- Take the lowest dose for the shortest time. Longer courses increase gut risk without adding extra benefit for many conditions.
- Prefer taking NSAIDs with food and water. This can reduce direct irritation of the gut lining.
- Avoid mixing several painkillers at the same time unless your doctor specifically advises it.
- Be cautious if you have prior gut disease, anemia, or regular stomach symptoms. Discuss alternatives early.
- Watch for warning signs: black stools, persistent abdominal pain, new diarrhea, or unexplained fatigue require medical review.
- After an NSAID period, focus on simple gut-friendly meals with vegetables, fruits, legumes, and whole grains as tolerated.
- Limit alcohol during NSAID use to reduce combined irritation of the gut.
- If long-term pain treatment is needed, ask about non-NSAID strategies such as physiotherapy, topical treatments, or other medication classes.
- Remember: protecting your gut is part of treating your pain.
References
[39] Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites. Cell. 2016. Link
Mechanistic review of short-chain fatty acids (SCFAs) — a major class of bacterial metabolites derived from dietary fibre fermentation — as central mediators between diet, gut microbiota, and host physiology. SCFAs activate G-protein-coupled receptors, inhibit histone deacetylases, and serve as energy substrates, thereby influencing metabolic, immune, and epigenetic processes. The authors synthesize evidence implicating SCFA-mediated signalling in both health maintenance and disease pathogenesis. Provides the conceptual backbone for fibre-based and microbiome-directed therapeutic strategies.
[144] Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007. Link
Cani and colleagues' 2007 Diabetes paper introduced the concept of 'metabolic endotoxemia' as a microbiota-driven trigger of obesity and insulin resistance. In mice, they show that a high-fat diet increases intestinal permeability and circulating lipopolysaccharide (LPS) levels, which activate TLR4-CD14 signalling and induce low-grade inflammation in adipose tissue, liver and muscle. Chronic subcutaneous LPS infusion in mice was sufficient to reproduce diet-induced obesity, insulin resistance and hepatic steatosis. CD14-knockout mice were protected. The paper established a mechanistic axis linking gut microbiota, barrier function and metabolic disease that has shaped subsequent obesity-microbiome research.
[227] Syer SD, Wallace JL, Vong L, McKnight W, Sharkey KA, Blackler RW. Concurrence of endoscopic and symptomatic ulcers with antibiotic treatment of Helicobacter pylori. Dig Dis Sci. 2015. Link
Syer and colleagues' 2015 Digestive Diseases and Sciences study examined concurrence of endoscopic and symptomatic ulcers during antibiotic treatment of Helicobacter pylori. The authors followed patients undergoing eradication therapy with endoscopy and symptom diaries, identifying that endoscopic ulcerations frequently co-occur with new or worsened upper-GI symptoms, including dyspepsia and pain. They highlight the mucosal-injury risk of the eradication regimen itself (clarithromycin, amoxicillin, PPI), distinct from H. pylori-driven inflammation. Implications include the importance of post-eradication symptom monitoring and consideration of mucosal-protective adjuncts. The work informs management of H. pylori treatment-related GI morbidity.
[228] Lanas A, Chan FKL. Peptic ulcer disease. Lancet. 2017. Link
Lanas and Chan's 2017 Lancet seminar reviews peptic ulcer disease (PUD), summarising current epidemiology, pathogenesis, diagnosis and management. They highlight the dominant roles of Helicobacter pylori and NSAID use, alongside contributions from low-dose aspirin, smoking, alcohol and psychological stress. The seminar covers eradication regimens for H. pylori (with attention to growing clarithromycin resistance), endoscopic management of bleeding ulcers, PPI use, and prevention strategies in NSAID/aspirin users. Emerging issues include the impact of antibiotic resistance, idiopathic ulcers and rebleed risk stratification. The review is a key clinical reference for gastroenterology guidelines on PUD.